About K. G. Jebsen TREC

Our vision  is to diminish patient suffering and burden of venous thrombosis in the society by discovering novel risk factors and disease mechanisms

Professor John-Bjarne Hansen  has conducted research on venous thrombosis (VTE) for several years leading the Hematological Research Group. In 2014 the group was awarded funding from the prestigious K. G. Jebsen Foundation to establish TREC- Thrombosis Research and Expertise Center.

Complicated, but common disease

The total suffering and economic burden caused by VTE is tremendous.  Approximately 540 000 VTE-related deaths occur in the EU each year. In comparison 68 000 deaths in the same area are caused by breast cancer.

20 to 50 % of the patients who suffer from VTE in the leg and thigh experience long time complications with pains and swellings caused by reduced circulation. Further, the Health burden related to treatment and loss of income due to the lack of ability to work is high.

Risk factors

Today, VTE is recognized as a multi causal disease involving both environmental and genetic factors, and interactions between them. However, in up to half of the patients with life-threatening VTE no risk factors has been identified, urgently warranting us to detect new risk factors as well as to investigate the interaction between the different risk factors. At TREC we will use well-studied and unique patient populations to identify how genomic regulators, miRNA expression, circulating micro particles, and proteomic expression affect VTE.

Family and twin studies indicates that genetic factors account for 60 % of the VTE risk. Although we know some of the genetic risk factors, they only help us to explain a small part of VTE related to heritance. The relation between genetic and environmental factors further increases the risk of VTE, but we still need to know more about this relation and its effect on VTE.


VTE is the formation of a blood clot in the deep veins, most often in the veins of the leg and thigh with swelling and pain in the affected limb as major symptoms. Parts of the blood clot might break away and travel along the venous blood stream to the lungs, where they lodge and block a pulmonary artery. Typical symptoms and signs are shortness of breath, respiratory-dependent chest pain, coughing of blood and, most seriously, fainting and, eventually, death due to circulatory collapse.     
Figure: Roy Lysaa     

Population health studies such as the Tromsø study, Helseundersøkelsen i Nord-Trøndelag (the HUNT study), and similar studies from Denmark and the Netherlands, forms part of our research material.


In Tromsø around 25 researchers will be connected to TREC. Our research will take place in Tromsø with the collaboration from our partners in Bodø (Norway), Oslo (Norway), the Netherlands and USA. Thus, we will form an international network of researchers with expertise in their fields to reach the aims of TREC.




Page administrator: Helle Jørgensen
Last updated: 20.03.2017 14:16